<DOC>
	<DOCNO>NCT02702960</DOCNO>
	<brief_summary>This trial phase II , single arm , open-label , single center study ass reduced-intensity conditioning regimen , bone marrow transplantation high dose PTCy recipients partial liver allograft Human Leukocyte Antigen ( HLA ) -matched -haploidentical living relate donor patient HCC . The primary objective trial characterize recurrence-free survival 1 year follow bone marrow transplantation among recipient prior partial liver transplantation donor .</brief_summary>
	<brief_title>Sequential , Related Donor Partial Liver Transplantation Followed Bone Marrow Transplantation Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>The purpose study characterize safety anti-tumor efficacy sequential partial liver transplantation follow bone marrow transplantation living relate donor . This treatment apply patient whose cancer remain confine liver widespread remove surgery treat liver transplant decease donor . The purpose combine treatment reduce risk cancer come back liver transplant The bone marrow transplant may reduce risk cancer relapse two way . First , patient combine bone marrow solid organ transplant may able get anti-rejection drug , inhibit immune system destroy cancer cell . Second , donor 's bone marrow contain cell immune system , attack cancer cell remain liver transplant . This trial phase II , single arm , open-label , single center pilot study ass reduced-intensity conditioning regimen , bone marrow transplantation high dose post-transplantation cyclophosphamide ( PTCy ) recipients partial liver allograft Human Leukocyte Antigen ( HLA ) -matched -haploidentical living relate donor patient HCC . The trial include analysis tumor characteristic number phenotype tumor infiltrate lymphocyte explanted tumor . The trial also include periodic monitoring circulate hepatocytes correlate tumor response . The study expect take two year complete accrual six patient , primary objective trial characterize recurrence-free survival 1 year follow bone marrow transplantation among recipient prior partial liver transplantation donor . Secondary objective include document percentage patient become tolerant transplanted liver , i.e . immunosuppression &gt; 6 month without biochemical evidence liver rejection , characterize relationship donor chimerism transplantation tolerance .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>RECIPIENT 1 . Histologic diagnosis liverconfined fibrolamellar nonfibrolamellar HCC . Ineligible curative resection decease donor liver transplantation virtue NOT meet Milan criterion downstaging criterion : 1 . Single viable tumor ≤5 cm size ≤3 tumor ≤3 cm size base CT Magnetic resonance ( MR ) image 2 . Pretransplant alpha fetoprotein ( AFP ) level ≤400 . 2 . Available human leukocyte antigen ( HLA ) match haploidentical , live related donor willing donate bone marrow part liver . The donor recipient must HLA identical least one allele ( use high resolution DNA base type ) follow genetic locus : HLAA , HLAB , HLAC HLADRB1 . Fulfilment criterion shall consider sufficient evidence donor recipient share one HLA haplotype . 3 . Age 16 65 year . 4 . Normal estimate leave ventricular ejection fraction ( &gt; 30 % ) history ischemic heart disease require revascularization , unless clear cardiologist ( per normal liver bone marrow ( BM ) transplant eligibility requirement ) . Those ejection fraction 3040 % , require cardiology consultation clearance transplantation . 5 . Forced expiratory volume ( FEV1 ) force vital capacity ( FVC ) &gt; 40 % predict screening visit . 6 . Serum creatinine &lt; 2.0 mg/dl 7 . For woman childbearing potential , negative serum urine pregnancy test sensitivity le 50 milliInternational unit ( mIU ) /m within 72 hour start study medication . 8 . Use two form contraception le 5 % failure rate abstinence transplant participant 12 month first dose study therapy . For first 60 day posttransplant , recipient encourage use nonhormonal contraceptive due potential adverse effect hormone bone marrow engraftment . 9 . Ability receive oral medication . 10 . Ability understand provide inform consent . 11 . Must meet criterion list liver transplantation DONOR : 1 . HLAmatched haploidentical , parent , child , sibling , halfsibling recipient 2 . Meets requirement live liver donation base establish criterion 3 . Ability understand provide inform consent study procedure include partial liver transplant bone marrow harvest . 4 . Age &lt; 60 year 5 . Body Mass Index ( BMI ) &lt; 35 RECIPIENT 1 . Extrahepatic disease time enrollment . 2 . Macrovascular invasion tumor see image 3 . Antidonor HLA antibody level produce positive test flow cytometric crossmatch . [ Note : patient positive flow cytometric crossmatch may undergo desensitization may become eligible , discretion protocol investigator , desensitization decrease antibody concentration level produce negative flow cytometric crossmatch . ] 4 . Ineligible liver transplantation per institutional criterion ( see Appendix 1 ) 5 . Women breastfeed . 6 . History positive HIV1 HIV2 serology nucleic acid test . 7 . Active hepatitis B infection document positive Hepatitis B assay 8 . Any active , severe local systemic infection screen visit . 9 . Use investigational drug , study medication specify protocol , within 30 day transplantation . 10 . Receipt live vaccine within 30 day receipt study therapy . 11 . The presence medical condition Investigator deem incompatible participation trial . DONOR 1 . Age : less age 18 old age 60 2 . BMI &gt; 35 3 . History blood product donation recipient 4 . Significant cardiovascular disease ( per cardiology consultation ) 5 . Significant pulmonary disease ( per pulmonology consultation ) 6 . Significant renal disease 7 . History diabetes mellitus 8 . Ongoing malignancy 9 . Severe local systemic infection 10 . Severe neurologic deficit 11 . Active substance abuse 12 . Untreatable/unstable psychiatric illness 13 . History positive HIV1 HIV2 serology nucleic acid test . 14 . Evidence prior hepatitis B infection evaluate hepatitis B surface antigen ( HBsAg ) , total hepatitis B core antibody , hepatitis B surface antibody ( antiHBsAb ) . 15 . Positive HBV PCR 16 . Positive antihepatitis C ( HCV ) antibodies positive serum HCV RNA PCR . All positive HCV antibody result must assess electroimmunoassay enzymelinked immunosorbent assay ( EIA ) assay confirm quantitative serum HCV RNA assay . Participants positive HCV antibody undetectable serum HCV RNA may consider eligibility . Participants negative antiHCV antibody unexplained liver enzyme abnormality must undergo quantitative serum RNA assay rule false negative HCV serology . 17 . Autoimmune disease require immunosuppressive drug maintenance . 18 . The presence medical condition Investigator deem incompatible participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>FL-HCC</keyword>
	<keyword>live donor liver transplant</keyword>
	<keyword>HLA match first degree relative</keyword>
	<keyword>Milan Criteria</keyword>
	<keyword>Ephraim Fuchs</keyword>
	<keyword>Fibrolamellar Cancer Foundation</keyword>
	<keyword>fibrolamellar</keyword>
	<keyword>non-fibrolamellar</keyword>
</DOC>